Generic placeholder image

Current Pharmaceutical Design


ISSN (Print): 1381-6128
ISSN (Online): 1873-4286

Cannabis in the Arm: What Can we Learn from Intravenous Cannabinoid Studies?

Author(s): Amir Englund, James M. Stone and Paul D. Morrison

Volume 18, Issue 32, 2012

Page: [4906 - 4914] Pages: 9

DOI: 10.2174/138161212802884618

Price: $65


Cannabis is widely used recreationally and for symptomatic relief in a number of ailments. However, cannabis has been implicated as a risk factor for the development of psychotic illness. For forty years researchers have utilised intravenous preparations of Δ9- THC, as well as several other phytocannabinoids, in a laboratory setting. The intravenous route has the most reliable pharmacokinetics, reducing inter-individual variation in bioavailability and is well suited for the delivery of synthetic compounds containing a sole pharmacological moiety. Given the association between cannabinoids and psychotic illness, there has been a resurgence of interest in experimental studies of cannabinoids in humans, and the intravenous route has been employed. Here in a critical review, we appraise the major findings from recent intravenous cannabinoid studies in humans and trace the historical roots of this work back to the 1970’s.

Keywords: Cannabis, Intravenous, delta-9-tetrahydrocannabinol, delta-9-tetrahydrocannabivarin, cannabidiol, THC, psychotic illness, phytocannabinoids, pharmacokinetics, intravenous route.

Rights & Permissions Print Export Cite as
© 2023 Bentham Science Publishers | Privacy Policy